BELGRADE, Feb 1(Reuters) - Tens of thousands of people blockaded three bridges on the Danube River in Serbia's second city of Novi Sad on Saturday in the latest anti-government protest over a ...

At least 400 students will be making the two-day march to Novi Sad in northern Serbia. One of the students taking part is Petar Gardovic, who is studying at the Faculty of Political Sciences at ...

On the first day of November, Aleksandar Matkovic was running late for a train. He was traveling from Novi Sad, in the north of Serbia, to its capital Belgrade, where he works as an economic ...

By Eshe Nelson Reporting from London Novo Nordisk, the Danish pharmaceutical company behind Ozempic and Wegovy, capped off a somewhat turbulent 2024, reporting profit and revenue on Wednesday that ...

Critics believe graft led to a sloppy job during the reconstruction of the Novi Sad train station, poor oversight and disrespect of existing safety regulations. The issue has come to symbolize a wider ...

Novo Nordisk reported strong data for its next-gen anti-obesity medicine. The Danish company has an excellent weight loss drug pipeline. But it's also diversifying its lineup and offering other ...

That haul helped Novo’s total sales for 2024 grow 26% at constant currencies to 290.4 billion kroner (nearly $41 billion), contributing to operating profits of 128.3 billion kroner ($18 billion ...

LISBON, Jan 31 (Reuters) - U.S. private equity firm Lone Star has told the Portuguese government that it is likely to sell a 25-30% stake in Novo Banco via an initial public offering, rather than ...

Novo Nordisk (NVO) ended the recent trading session at $84.62, demonstrating a -1.9% swing from the preceding day's closing price. This change lagged the S&P 500's daily gain of 0.16%. At the same ...

(Reuters) -The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as death due to heart problems in diabetes patients with ...

In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is rolling out new data on a higher-dose injection in obesity. In the phase 3b ...

Novo Nordisk presents a compelling 'Strong Buy' opportunity with a 51% upside potential. NVO's financial strength is evident through its 74% historical average ROIC, 85% gross margin, and ...